The importance of endoscopic ultrasound in detecting recurrent gastrinoma in a case of MEN 1 Abstract #135

Introduction: Approximately 25-30% of patients have gastrinomas as part of the inherited syndrome Multiple Endocrine Neoplasia 1 (MEN 1). Gastrinomas occur in the pancreas, duodenum or peripancreatic lymph nodes. Diagnosis is made by clinical history, gastroscopy, and measurement of serum gastrin, gastric juice pH, CT scan, endoscopic ultrasound (EUS) and somatostatin receptor scintigraphy (SRS). Localization of gastrinomas in patients with MEN 1 is challenging due to their small size, frequent duodenal location, and multiplicity.
Aim(s): To report the diagnostic difficulties and role of EUS in a clinical case of recurrent gastrinoma in MEN 1.
Materials and methods: EUS with FNA biopsy was carried out by an experienced endoscopic team at the digestive endoscopic unit of our hospital.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Laura De Marinis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#543 Endoscopic Ultrasound-Guided Fine Needle Tissue Acquisition (EUS-FNTA) Using a 19-G Needle for Histological Grading of Pancreatic Endocrine Tumors (PETs): A Prospective Study
Introduction: EUS-FNTA is increasingly used in the diagnosis of pancreatic endocrine tumors (PETs). Ki-67 expression, an important prognostic factor according to the WHO classification, is difficult to be determined on cytological specimens.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Laura De Marinis
Authors: Larghi A, Fusco A, Bianchi A, Lugli F, ...
Keywords: EUS, Ki-67, grading, pancreas
#2733 Pancreatic Metastases Originating from Intestinal Neuroendocrine Tumours
Introduction: Pancreatic metastases are rare, accounting for 1 to 2% of pancreatic tumours. Data on pancreatic metastases of intestinal NETs are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Anja Rinke
#2852 Diagnostic Accuracy of Endoscopic Ultrasound-Fine Needle Aspiration (EUS-FNA) in the Evaluation of Pancreatic Neuroendocrine Neoplasms (PNEN) Grading
Introduction: Prognosis of pNENs depends on staging and grading, based on the cyto-histological Ki67 labelling; EUS-FNA is considered the gold standard technique to obtain it in pre-therapeutic setting
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Matteo Tacelli
#142 The role of 18F DOPA-PET in a case of malignant pheochromcytoma
Introduction: Pheocromocytoma is a rare tumor arising from chromaffin cells of adrenal medullary or extra adrenal paraganglionic tissue. Histological criteria cannot differentiate benign from malignant pheocromocytomas. The diagnosis of a malignant pheocromocytoma requires local invasion, recurrence and documented metastatic disease. The radionuclide scanning (123I - 131I-MIBG) is a fundamental diagnostic tool used to confirm the biochemical and radiological diagnosis of pheochromocytoma. In fact, MIBG scanning may confirm that the visualised lesion in an adrenal gland is indeed a pheochromocytoma and detect extra-adrenal paraganglionic tissue. However, MIBG scans are negative in around 15% of benign pheochromocytomas and in up to 50% of malignant ones. Other radionuclide techniques (18FDG-PET, 18F-DOPA-PET, 18F-FDA-PET) have been successfully used in investigation of pheochromocytomas. 18F-DOPA-PET and 18F-FDA-PET have been reported to be highly sensitive and specific for benign pheochromocytomas, while 18FDG-PET can be useful for malignant lesions with higher metabolic activity.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Laura De Marinis
#301 Medical and Peptide Receptor Radionuclide Therapy (PRRT) with Somatostatin Analogues (SSA) in Well- and Moderately Differentiated Neuroendocrine Tumors
Introduction: PRRT is a treatment choice for inoperable or metastasized neuroendocrine tumors and this therapy seems more effective in the biochemical and volume control of disease than SSA alone.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof Laura De Marinis